ClinicaliQ Trial Snapshot
- A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes — Recruiting • Phase III • Diabetes / Metabolic • NCT07743450.
- What is being tested: ASC30, an oral once-daily medication, is being evaluated for efficacy and safety in reducing weight and improving glycaemic control in adults with type 2 diabetes who are overweight or obese, compared to placebo in a Phase III randomised….
- Patient eligibility overview: The study enrolls adult participants with concurrent type 2 diabetes and obesity or overweight status, with three different maintenance doses of ASC30 being investigated across multiple global centres in a double-blind design.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral ASC30 compared with placebo in participants with obesity or overweight and T2DM.
Eligibility Snapshot
- :
- Participant must be ≥18 years of age inclusive, or the legal age of consent in the jurisdiction in which the study is taking place at screening. 2. Have a BMI ≥ 27 kg/m2 at screening. 3. Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight. 4. Have a diagnosis of T2D according to the WHO classification or other locally applicable standards, with HbA1c > 6.5% (48 mmol/mol) to ≤10.5% (91 mmol/mol) at screening.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.